CASI Pharmaceuticals, Inc. SEC filings CASIF

CASI Pharmaceuticals, Inc. has 157 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.

CASI Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
424B5 Prospectus supplement Apr 1, 2025 —
F-3/A Form f-3/a Dec 23, 2024 —
F-3 Shelf registration (foreign issuer) Dec 20, 2024 —
F-3/A Filing Aug 29, 2024 —
F-3 Shelf registration (foreign issuer) Aug 16, 2024 —
S-8 Employee stock plan registration Aug 14, 2024 —
F-3 Shelf registration (foreign issuer) May 3, 2024 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Filing Mar 21, 2023 —
S-8 POS Filing Mar 21, 2023 —
S-8 POS Filing Mar 21, 2023 —
S-8 POS Filing Mar 21, 2023 —
424B3 Prospectus Feb 14, 2023 —
F-4/A Filing Feb 9, 2023 —
F-4 Filing Jan 31, 2023 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CASIF (OTC)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Beijing, China
SEC filer status
Non-accelerated filer
SEC CIK
1962738
Former names
CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.